How long you can live with aggressive prostate cancer depends heavily on when it’s caught and how far it has spread. For distant-stage prostate cancer (cancer that has metastasized to other parts of the body), the five-year relative survival rate is about 38%, based on National Cancer Institute data. For aggressive cancers still confined to the prostate or nearby tissue, many men live well beyond a decade with treatment. The range is wide because “aggressive” covers several different clinical situations, each with its own trajectory.
What Makes Prostate Cancer “Aggressive”
Aggressive prostate cancer is defined by specific clinical markers, not just a general impression. The National Comprehensive Cancer Network classifies localized prostate cancer as high-risk when the biopsy shows a Gleason score of 8 or higher, the PSA level exceeds 20, or imaging shows the tumor has grown through the prostate wall. Very high-risk disease involves even more concerning features: a primary Gleason pattern of 5 (the most disorganized cell growth), five or more biopsy cores showing high-grade cancer, or multiple high-risk features stacked together.
These distinctions matter because a Gleason 8 cancer caught early in one man can behave very differently from a Gleason 9 cancer discovered after it has spread to bone. Both are “aggressive,” but the expected survival timelines are years apart.
Survival When the Cancer Is Still Localized
When aggressive prostate cancer hasn’t yet spread beyond the prostate or nearby lymph nodes, outcomes are considerably better than most people expect. Men with Gleason 8 to 10 disease who undergo surgery often have years of follow-up without the cancer returning. In one surgical study of 104 men with Gleason 8 to 10 tumors, the median follow-up reached 65 months (about five and a half years), with most of those cancers being Gleason 9, the second-highest grade.
Genomic testing can further refine the picture. Tests that analyze the tumor’s gene activity can estimate 10-year metastasis risk. Men whose tumors score low on these tests have a distant metastasis rate of around 4 to 6% at 10 years, even with radiation alone. Those with high genomic scores face a 16 to 26% chance of the cancer spreading within a decade, but adding hormone therapy significantly reduces that risk.
Survival After the Cancer Has Spread
Once aggressive prostate cancer metastasizes, the timeline shortens but remains highly variable. The 38% five-year survival rate for distant-stage disease is an average across all metastatic patients. Some men live many years; others face a faster course. The initial response to hormone therapy is one of the strongest predictors of what comes next.
Most metastatic prostate cancers initially respond to treatments that block testosterone, since the hormone fuels tumor growth. This phase can last months to several years. The critical turning point comes when the cancer stops responding to hormone suppression, a stage called castration-resistant disease. At that point, the median life expectancy is roughly three years, according to Mayo Clinic data, though newer treatments are stretching that number.
How PSA Speed Predicts Outcome
One of the most useful prognostic tools is PSA doubling time, which measures how quickly the PSA level in your blood doubles. A fast doubling time signals that the cancer is growing rapidly. The risk of dying from prostate cancer within five years of a recurrence is about 50% when PSA doubles in 12 months or less, compared to just 10% when it takes longer than 12 months to double.
For men with castration-resistant disease on chemotherapy, the numbers are even more telling. Those with a very short PSA doubling time (under about 45 days) had a median survival of 16.5 months, compared to 26 months for men whose PSA rose more slowly. A doubling time under three months after surgery carries a particularly high hazard, roughly 25 times the risk of cancer death compared to men with slower-growing recurrences.
The Role of Genetic Mutations
Inherited mutations in the BRCA2 gene, better known for their connection to breast cancer, significantly worsen the outlook for prostate cancer. Men with prostate cancer and a BRCA2 mutation had a 12-year cancer-specific survival rate of just 62%, compared to 94% for men without the mutation. Even after adjusting for age, PSA level, and tumor grade, carrying a BRCA2 mutation roughly tripled the risk of dying from prostate cancer.
Among men with high-grade disease (Gleason 7 to 9) specifically, a BRCA2 mutation increased the risk of cancer death more than fourfold. A quarter of BRCA2 carriers already had metastatic cancer at diagnosis, and their 12-year survival was only 33%. BRCA2 mutations account for a small fraction of all prostate cancers (about 1.4%) but are responsible for roughly 8% of prostate cancer deaths, a disproportionate toll that makes genetic testing increasingly important for men with aggressive disease.
How Treatment Extends Survival
Treatment for aggressive prostate cancer has improved substantially over the past decade, and the options available at each stage affect how long men live. For localized high-risk disease, surgery or radiation combined with long-term hormone therapy remains the standard approach and can be curative for many men.
For metastatic castration-resistant disease, newer therapies are pushing survival further. A targeted radioligand therapy tested in a large clinical trial extended median overall survival from 11.3 months to 15.3 months in men with advanced disease who had already been through other treatments. It also more than doubled the time before the cancer visibly progressed on imaging, from 3.4 months to 8.7 months. These gains may sound modest in isolation, but they stack with earlier treatments. Men who respond well to a sequence of therapies can accumulate years of additional life compared to what would have been possible a decade ago.
The combination of treatments matters more than any single therapy. Men who receive hormone therapy, chemotherapy, and newer targeted agents in sequence generally live longer than those who respond to only one line of treatment. How well the cancer responds to each step largely determines the overall trajectory.
What Shapes Individual Outcomes
Averages and medians describe populations, not individuals. Several factors push survival in one direction or the other:
- Stage at diagnosis: Aggressive cancer caught before it spreads has a fundamentally different outlook than cancer discovered after metastasis. The gap between localized and distant-stage survival is measured in years, sometimes decades.
- Tumor biology: Two cancers with the same Gleason score can behave differently based on their underlying genetic profile. Genomic tests help distinguish tumors likely to stay contained from those prone to spreading.
- Treatment response: Men whose PSA drops quickly and deeply after starting hormone therapy tend to have longer survival than those with a partial response.
- Overall health: Age and other medical conditions affect which treatments are feasible, and men in better overall health tend to tolerate the full range of available therapies.
- Location of metastases: Cancer that spreads to bone carries a worse prognosis than cancer limited to lymph nodes. Spread to the liver or lungs is associated with the shortest survival times.
For a man with high-grade localized prostate cancer who receives aggressive treatment, living 10 to 15 years or more is realistic. For a man with widespread metastatic castration-resistant disease, the timeline is typically measured in years rather than decades, with a median around three years and meaningful variation on either side of that number.